Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Inhibition of the BRAF(V600E) oncoprotein by the small-molecule drug PLX4032 (vemurafenib) is highly effective in the treatment of melanoma. However, colon cancer patients harbouring the same BRAF(V600E) oncogenic lesion have poor prognosis and show only a very limited response to this drug. To investigate the cause of the limited therapeutic effect of PLX4032 in BRAF(V600E) mutant colon tumours, here we performed an RNA-interference-based genetic screen in human cells to search for kinases whose knockdown synergizes with BRAF(V600E) inhibition. We report that blockade of the epidermal growth factor receptor (EGFR) shows strong synergy with BRAF(V600E) inhibition. We find in multiple BRAF(V600E) mutant colon cancers that inhibition of EGFR by the antibody drug cetuximab or the small-molecule drugs gefitinib or erlotinib is strongly synergistic with BRAF(V600E) inhibition, both in vitro and in vivo. Mechanistically, we find that BRAF(V600E) inhibition causes a rapid feedback activation of EGFR, which supports continued proliferation in the presence of BRAF(V600E) inhibition. Melanoma cells express low levels of EGFR and are therefore not subject to this feedback activation. Consistent with this, we find that ectopic expression of EGFR in melanoma cells is sufficient to cause resistance to PLX4032. Our data suggest that BRAF(V600E) mutant colon cancers (approximately 8-10% of all colon cancers), for which there are currently no targeted treatment options available, might benefit from combination therapy consisting of BRAF and EGFR inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“BRAF inhibition in BRAFV600 mutant cancers leads to loss of negative feedback signals regulated by the MAPK pathway, leading to receptor tyrosine kinase (RTK)-mediated reactivation of MAPK signaling through wild type RAS and RAF, particularly in specific tumor types, such as colorectal cancer (9–12).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, RTK-driven feedback reactivation of RAS-MAPK signaling has been identified as a key driver of resistance in BRAFV600E cancers treated with BRAF inhibitors (colorectal cancer in particular) and in KRAS-mutant cancers treated with MEK inhibitors (11,12,32).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This finding is consistent with prior studies identifying HER family and FGFR signaling as key mediators of adaptive feedback to RAS-MAPK pathway inhibitors (10–14,21,22) and recent functional genomic screens(40).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, adaptive feedback resistance has been a key limitation in prior clinical efforts to target the RAS-MAPK pathway.”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The prevalence of BRAF V600E mutations in mCRC is 8–10%, and they occur only in KRAS-WT mCRC [159,160].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [159]
Experimental — accuracy not yet measured
23 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674 · cited 1×
“shRNA inserts were retrieved from 8mg genomic DNA by PCR amplification (PCR1 and PCR2, see below for primer information) using the following conditions: (1) 98 uC, 30 s; (2) 98 uC, 10 s; (3) 60 uC, 20 s; (4) 72 uC, 1 min; (5) to step (2), 15 cycles; (6) 72 uC, 5 min; (7) 4 uC.”
The protein kinase complement of the human genome
Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002) · Science · doi:10.1126/science.1075762 · Cited by 8,145
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207 · cited 1×
“Figure 1e shows that inhibition of EGFR does not significantly affect proliferation of EGFR in WiDr cells, consistent with the clinical observations that KRAS or BRAF mutant CRC cells do not respond to EGFR-targeted monoclonal antibodie”
ResultEpidermal growth factor-related peptides and their receptors in human malignancies
Salomon, D. S., Brandt, R., Ciardiello, F., & Normanno, N. (1995) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(94)00144-i · Cited by 2,690
Kimura, E. T., Nikiforova, M. N., Zhu, Z., Knauf, J. A., Nikiforov, Y. E., & Fagin, J. A. (2003) · PubMed · Cited by 1,707
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., De Dosso, S., Mazzucchelli, L., Frattini, M., Siena, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0786 · Cited by 1,591 · cited 1×
“shRNA inserts were retrieved from 8mg genomic DNA by PCR amplification (PCR1 and PCR2, see below for primer information) using the following conditions: (1) 98 uC, 30 s; (2) 98 uC, 10 s; (3) 60 uC, 20 s; (4) 72 uC, 1 min; (5) to step (2), 15 cycles; (6) 72 uC, 5 min; (7) 4 uC.”
Self-citationThe Concept of Synthetic Lethality in the Context of Anticancer Therapy
Kaelin, W. G. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1691 · Cited by 1,379
Roth, A. D., Tejpar, S., Delorenzi, M., Yan, P., Fiocca, R., Klingbiel, D., Dietrich, D., Biesmans, B., Bodoky, G., Barone, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.3452 · Cited by 1,158
Cited by
Items 301–400 of 1,012
Li, F., Huynh, H., Li, X., Ruddy, D. A., Wang, Y., Ong, R., Chow, P., Qiu, S., Tam, A., Rakiec, D. P., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0763 · Cited by 107
Tothill, R. W., Li, J., Mileshkin, L., Doig, K., Siganakis, T., Cowin, P. A., FELLOWES, A. P., Semple, T. J., Fox, S. B., Byron, K. A., et al. (2013) · The Journal of Pathology · doi:10.1002/path.4251 · Cited by 113
Activating BRAF and PIK3CA Mutations Cooperate to Promote Anaplastic Thyroid Carcinogenesis
Charles, R.-P., Silva, J., Iezza, G., Phillips, W. A., & McMahon, M. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0158-t · Cited by 104
Systematic analysis of somatic mutations impacting gene expression in 12 tumour types
Ding, J., McConechy, M. K., Horlings, H. M., Ha, G., Chan, F. C., Funnell, T., Mullaly, S. C., Reimand, J., Bashashati, A., Bader, G. D., et al. (2015) · Nature Communications · doi:10.1038/ncomms9554 · Cited by 117
Targeting the PI3K/Akt/mTOR Pathway for Breast Cancer Therapy
Cidado, J. R., & Park, B. H. (2012) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-012-9264-2 · Cited by 120
Rare cancers: a sea of opportunity
Boyd, N., Dancey, J. E., Gilks, C. B., & Huntsman, D. D. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00386-1 · Cited by 114
Wang, C., Wang, H., Lieftink, C., du Chatinier, A., Gao, D., Jin, G., Jin, H., Beijersbergen, R. L., Qin, W., & Bernards, R. (2020) · Gut · doi:10.1136/gutjnl-2019-318506 · Cited by 107
Self-citationWang, Y., Sun, S., Luo, J., Xiong, Y., Tao, M., Liu, J., Ma, Y., Yan, S., Yang, Y., Yang, Z., et al. (2020) · Microsystems & Nanoengineering · doi:10.1038/s41378-020-0146-2 · Cited by 107
Combinatorial strategies to target RAS-driven cancers
Perurena, N., Situ, L., & Cichowski, K. M. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00679-6 · Cited by 115
Beckman, R. A., Schemmann, G. S., & Yeang, C. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1203559109 · Cited by 115
Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer
Lin, L., Asthana, S., Chan, E., Bandyopadhyay, S., Martins, M. M., Olivas, V., Yan, J. J., Pham, L., Wang, M. M., Bollag, G., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320956111 · Cited by 105
Dramatic Response Induced by Vemurafenib in a BRAF V600E-Mutated Lung Adenocarcinoma
Peters, S., Michielin, O. A., & Zimmermann, S. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.6143 · Cited by 111
Present and future of metastatic colorectal cancer treatment: A review of new candidate targets
Martini, G., Troiani, T., Cardone, C., Vitiello, P. P., Sforza, V., Ciardiello, D., Napolitano, S., Corte, C. M. D., Morgillo, F., Raucci, A., et al. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i26.4675 · Cited by 117
Molecular targeted therapy of BRAF-mutant colorectal cancer
Ducreux, M., Chamseddine, A., Laurent-Puig, P., Smolenschi, C., Hollebecque, A., Dartigues, P., Samallin, E., Boige, V., Malka, D., & Gelli, M. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919856494 · Cited by 100
Van Schaeybroeck, S., Kalimutho, M., Dunne, P. D., Carson, R., Allen, W., Jithesh, P. V., Redmond, K. L., Sasazuki, T., Shirasawa, S., Blayney, J., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.05.032 · Cited by 106
“In contrast to a recent study by Prahallad et al. (2012), we did not observe involvement of the phosphatase CDC25C in regulating the feedback activation of c-MET, JAK1/2, and STAT3 in the context of MEKi treatment (data not shown).”
ResultWu, Q., Zhen, Y., Shi, L., Vu, P., Greninger, P., Adil, R., Merritt, J., Egan, R., Wu, M.-J., Yin, X., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1168 · Cited by 104
Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines
Campbell, J., Ryan, C. J., Brough, R., Bajrami, I., Pemberton, H. N., Chong, I. Y., Costa-Cabral, S., Frankum, J., Gulati, A., Holme, H., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.02.023 · Cited by 101
BRAFV600E cooperates with CDX2 inactivation to promote serrated colorectal tumorigenesis
Sakamoto, N., Feng, Y., Stolfi, C., Kurosu, Y., Green, M. E., Lin, J., Green, M. E., Sentani, K., Yasui, W., McMahon, M., et al. (2017) · eLife · doi:10.7554/elife.20331 · Cited by 112
Cabanillas, M. E., Dadu, R., Iyer, P., Wanland, K. B., Busaidy, N. L., Ying, A. K., Gule-Monroe, M. K., Wang, J. R., Zafereo, M., & Hofmann, M.-C. C. (2020) · Thyroid · doi:10.1089/thy.2019.0514 · Cited by 107
Van Cutsem, E., Taieb, J., Yaeger, R., Yoshino, T., Grothey, A., Maiello, E., Elez, E., Dekervel, J., Ross, P., Ruiz-Casado, A., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01693 · Cited by 103
Pietrantonio, F., Oddo, D., Gloghini, A., Valtorta, E., Berenato, R., Barault, L., Caporale, M., Busico, A., Morano, F., Gualeni, A. V., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0297 · Cited by 103
Self-citationde Jong, P. R., Taniguchi, K., Harris, A. R., Bertin, S., Takahashi, N., Duong, J., Campos, A. D., Powis, G., Corr, M., Karin, M., et al. (2016) · Nature Communications · doi:10.1038/ncomms11551 · Cited by 113
Current Insights of BRAF Inhibitors in Cancer
Agianian, B., & Gavathiotis, E. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01306 · Cited by 112
Epigenetic Changes of EGFR Have an Important Role in BRAF Inhibitor–Resistant Cutaneous Melanomas
Wang, J., Huang, S. K., Marzese, D. M., Hsu, S. C., Kawas, N. P., Chong, K. K., Long, G. V., Menzies, A. M., Scolyer, R. A., Izraely, S., et al. (2014) · Journal of Investigative Dermatology · doi:10.1038/jid.2014.418 · Cited by 113
Self-citationJACKS: joint analysis of CRISPR/Cas9 knockout screens
Allen, F., Behan, F. M., Khodak, A., Iorio, F., Yusa, K., Garnett, M. J., & Parts, L. (2019) · Genome Research · doi:10.1101/gr.238923.118 · Cited by 109
The Future of Clinical Trial Design in Oncology
Spreafico, A., Hansen, A. R., Razak, A. R. A., Bedard, P. L., & Siu, L. L. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1301 · Cited by 119
RAF inhibitors promote RAS-RAF interaction by allosterically disrupting RAF autoinhibition
Jin, T., Lavoie, H., Sahmi, M., David, M., Hilt, C., Hammell, A., & Therrien, M. (2017) · Nature Communications · doi:10.1038/s41467-017-01274-0 · Cited by 102
Tolcher, A. W., Peng, W., & Calvo, E. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0349 · Cited by 99
Korkut, A., Wang, W., Demir, E., Aksoy, B. A., Jing, X., Molinelli, E. J., Babur, Ö., Bemis, D. L., Onur Sumer, S., Solit, D. B., et al. (2015) · eLife · doi:10.7554/elife.04640 · Cited by 100
Waizenegger, I. C., Baum, A., Steurer, S., Stadtmüller, H., Bader, G., Schaaf, O., Garin-Chesa, P., Schlattl, A., Schweifer, N., Haslinger, C., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0617 · Cited by 97
New drugs for children and adolescents with cancer: the need for novel development pathways
Vassal, G., Zwaan, C. M., Ashley, D. M., Deley, M. L., Hargrave, D. R., Blanc, P., & Adamson, P. C. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70013-5 · Cited by 104
Molecular Pathways: BRAF Induces Bioenergetic Adaptation by Attenuating Oxidative Phosphorylation
Haq, R., Fisher, D. E., & Widlund, H. R. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0898 · Cited by 105
Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies
Brandi, G., Farioli, A., Astolfi, A., Biasco, G., & Tavolari, S. (2015) · Oncotarget · doi:10.18632/oncotarget.4539 · Cited by 101
Wang, C., Jin, H., Gao, D., Lieftink, C., Evers, B., Jin, G., Zheng, X., Wang, L., Beijersbergen, R. L., Qin, W., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.07.004 · Cited by 103
Self-citationNeurofibromin and suppression of tumorigenesis: beyond the GAP
Mo, J., Moye, S. L., McKay, R. M., & Le, L. Q. (2022) · Oncogene · doi:10.1038/s41388-021-02156-y · Cited by 100
Molecular Pathways: Mitogen-Activated Protein Kinase Pathway Mutations and Drug Resistance
Pritchard, A. L., & Hayward, N. K. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0383 · Cited by 112
Outcomes and endpoints in cancer trials: bridging the divide
Wilson, M. K., Collyar, D. E., Chingos, D. T., Friedlander, M. L., Ho, T. W., Karakasis, K., Kaye, S. B., Parmar, M., Sydes, M. R., Tannock, I. F., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70380-8 · Cited by 111
Transcriptional landscape of human cancers
Li, M., Sun, Q., & Wang, X. (2017) · Oncotarget · doi:10.18632/oncotarget.15837 · Cited by 101
Turning liabilities into opportunities: Off-target based drug repurposing in cancer
Palve, V. C., Liao, Y., Rix, L. L. R., & Rix, U. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.02.003 · Cited by 103
Exploring and modelling colon cancer inter-tumour heterogeneity: opportunities and challenges
Buikhuisen, J. Y., Torang, A., & Medema, J. P. (2020) · Oncogenesis · doi:10.1038/s41389-020-00250-6 · Cited by 107
Trial watch: Monoclonal antibodies in cancer therapy
Vacchelli, E., Eggermont, A. M. M., Galon, J., Sautès‐Fridman, C., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.22789 · Cited by 109
Cracking the EGFR code: Cancer biology, resistance mechanisms, and future therapeutic frontiers
Du, Y.-F., Karatekin, F., Wang, W. K., Hong, W., & Gandhi, T. K. B. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100076 · Cited by 115
Conway, A., Mitchell, C. L., Kilgour, E., Brady, G., Dive, C., & Cook, N. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0332-2 · Cited by 109
Widyananda, M. H., Pratama, S. K., Samoedra, R. S., Sari, F. N., Kharisma, V. D., Ansori, A. N. M., & Antonius, Y. (2021) · Journal of Pharmacy & Pharmacognosy Research · doi:10.56499/jppres21.1047_9.4.484 · Cited by 96
Feng, J., Hu, Z., Xia, X., Liu, X., Lian, Z., Wang, H., Wang, L., Wang, C., Zhang, X., & Pang, X. (2023) · Oncogene · doi:10.1038/s41388-023-02676-9 · Cited by 95
“Oncogene (2023) 42:1620 – 1633 Notably, only ERRFI1 mRNA expression decreased in a timedependent manner, both in vitro and in vivo, unlike the inconsistent expression patterns of CDC25C and CBL (Fig.”
BackgroundPongor, L. S., Kormos, M., Hatzis, C., Pusztai, L., Szabó, A., & Győrffy, B. (2015) · Genome Medicine · doi:10.1186/s13073-015-0228-1 · Cited by 106
Rossi, A., Roberto, M., Panebianco, M., Botticelli, A., Mazzuca, F., & Marchetti, P. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172621 · Cited by 99
Targeting the EGFR signalling pathway in metastatic colorectal cancer
Napolitano, S., Martini, G., Ciardiello, D., Tufo, S. D., Martinelli, E., Troiani, T., & Ciardiello, F. (2024) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(23)00479-x · Cited by 108
Yaeger, R., Yao, Z., Hyman, D. M., Hechtman, J. F., Vakiani, E., Zhao, H., Su, W., Wang, L., Joelson, A., Cercek, A., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0768 · Cited by 94
“EGFR is the dominant RTK in colon and the marked rebound in ERK signaling is thought to be due predominantly to relief of feedback inhibition of this receptor(11, 12).”
BackgroundGenomic Determinants of PI3K Pathway Inhibitor Response in Cancer
Weigelt, B., & Downward, J. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00109 · Cited by 91
Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials
Tourneau, C. L., Kamal, M. T., Tsimberidou, A. M., Bedard, P. L., Pierron, G., Callens, C., Rouleau, É., Vincent‐Salomon, A., Servant, N., Alt, M., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv362 · Cited by 99
Understanding the Genetic Mechanisms of Cancer Drug Resistance Using Genomic Approaches
Hu, X., & Zhang, Z. (2015) · Trends in Genetics · doi:10.1016/j.tig.2015.11.003 · Cited by 98
BRAF Mutations: Signaling, Epidemiology, and Clinical Experience in Multiple Malignancies
Hall, R. D., & Kudchadkar, R. R. (2014) · Cancer Control · doi:10.1177/107327481402100307 · Cited by 93
A Systematic Analysis of Oncogenic Gene Fusions in Primary Colon Cancer
Kloosterman, W. P., Coebergh van den Braak, R. R. J., Pieterse, M., van Roosmalen, M. J., Sieuwerts, A. M., Stangl, C., Brunekreef, R., Lalmahomed, Z. S., Ooft, S., van Galen, A., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3563 · Cited by 94
Klempner, S. J., Gershenhorn, B. G., Tran, P. N., Lee, T. K. M., Erlander, M. G., Gowen, K. A., Schrock, A. B., Morosini, D., Ross, J. S., Miller, V. A., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1192 · Cited by 99
Servant, N., Roméjon, J., Gestraud, P., Rosa, P. L., Lucotte, G., Lair, S., Bernard, V., Zeitouni, B., Coffin, F., Jules-Clément, G., et al. (2014) · Frontiers in Genetics · doi:10.3389/fgene.2014.00152 · Cited by 96
Niepel, M., Hafner, M., Duan, Q., Wang, Z., Paull, E. O., Chung, M., Lu, X., Stuart, J. M., Golub, T. R., Subramanian, A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01383-w · Cited by 97
BRAF -Mutated Advanced Colorectal Cancer: A Rapidly Changing Therapeutic Landscape
Ciombor, K. K., Strickler, J. H., Bekaii-Saab, T. S., & Yaeger, R. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02541 · Cited by 92
Gong, K., Guo, G., Panchani, N., Bender, M. E., Gerber, D. E., Minna, J. D., Fattah, F., Gao, B., Peyton, M., Kernstine, K., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0048-0 · Cited by 92
The Emerging Potential for Network Analysis to Inform Precision Cancer Medicine
Öztürk, K., Dow, M. T., Carlin, D. E., Bejar, R. L., & Carter, H. K. (2018) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.06.016 · Cited by 98
Brandt, R., Sell, T., Lüthen, M., Uhlitz, F., Klinger, B., Riemer, P., Giesecke-Thiel, C., Schulze, S., El-Shimy, I. A., Kunkel, D., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10954-y · Cited by 91
Combining Allosteric and Orthosteric Drugs to Overcome Drug Resistance
Ni, D., Li, Y., Qiu, Y., Pu, J., Lu, S., & Zhang, J. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.02.001 · Cited by 95
The ERK cascade inhibitors: Towards overcoming resistance
Maik-Rachline, G., & Seger, R. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2015.12.001 · Cited by 96
Analyzing and validating the prognostic value and mechanism of colon cancer immune microenvironment
Wang, X., Duanmu, J., Fu, X., Li, T., & Jiang, Q. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02491-w · Cited by 102
Precision cancer medicine: Concepts, current practice, and future developments
Edsjö, A., Holmquist, L., Geoerger, B., Nowak, F., Gomon, G., Alix‐Panabières, C., Staaf, J., Ploeger, C., Lassen, U., Tourneau, C. L., et al. (2023) · Journal of Internal Medicine · doi:10.1111/joim.13709 · Cited by 99
Intratumoral Heterogeneity as a Therapy Resistance Mechanism
Somasundaram, R., Villanueva, J., & Herlyn, M. (2012) · Advances in pharmacology · doi:10.1016/b978-0-12-397927-8.00011-7 · Cited by 106
Synthetic Lethality and Cancer – Penetrance as the Major Barrier
Ryan, C. J., Bajrami, I., & Lord, C. J. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.08.003 · Cited by 94
Tabernero, J. M., García‐Carbonero, R., Cassidy, J., Sobrero, A. F., Cutsem, E. V., Köhne, C.-H., Tejpar, S., Gladkov, O. A., Давиденко, І., Salazar, R., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0107 · Cited by 95
Self-citationGenomically Driven Tumors and Actionability across Histologies:BRAF-Mutant Cancers as a Paradigm
Turski, M. L., Vidwans, S. J., Jankú, F., Garrido‐Laguna, I., Munoz, J., Schwab, R. B., Subbiah, V., Rodon, J. A., & Kurzrock, R. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0643 · Cited by 94
Systematic review of combinations of targeted or immunotherapy in advanced solid tumors
Tan, A. C., Bagley, S. J., Wen, P. Y., Lim, M. K., Platten, M., Colman, H., Ashley, D. M., Wick, W., Chang, S. M., Galanis, E., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002459 · Cited by 96
Dayton, T. L., Alcala, N., Moonen, L., den Hartigh, L., Geurts, V., Mangiante, L., Lap, L. M. V., Dost, A. F. M., Beumer, J., Levy, S., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.11.007 · Cited by 93
Digestive cancers: mechanisms, therapeutics and management
Zhan, T., Betge, J., Schulte, N., Dreikhausen, L., Hirth, M., Li, M., Weidner, P., Leipertz, A., Teufel, A., & Ebert, M. P. A. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02097-4 · Cited by 100
Standardized decision support in next generation sequencing reports of somatic cancer variants
Dienstmann, R., Dong, F., Borger, D., Dias-Santagata, D., Ellisen, L. W., Le, L. P., & Iafrate, A. J. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.03.021 · Cited by 89
Approach to the Patient with Anaplastic Thyroid Carcinoma
Smallridge, R. C. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1314 · Cited by 90
Vignot, S., Besse, B., André, F., Spano, J., & Soria, J. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.05.002 · Cited by 96
A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility
Vecchione, L., Gambino, V., Raaijmakers, J. A., Schlicker, A., Fumagalli, A., Russo, M., Villanueva, A., Beerling, E., Bartolini, A., Molleví, D. G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.059 · Cited by 91
Self-citationSmyth, T., Paraiso, K. H. T., Hearn, K., Rodriguez-Lopez, A. M., Munck, J. M., Haarberg, H. E., Sondak, V. K., Thompson, N. T., Azab, M., Lyons, J. F., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0452 · Cited by 90
Development of Dual Inhibitors Targeting Epidermal Growth Factor Receptor in Cancer Therapy
Tan, L., Zhang, J., Wang, Y., Wang, X., Wang, Y., Zhang, Z., Shuai, W., Wang, G., Chen, J., Wang, C., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01714 · Cited by 88
Epidermal Growth Factor Receptor: Pathway, Therapies, and Pipeline
Goffin, J. R., & Zbuk, K. M. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.08.007 · Cited by 105
Colorectal Cancer Biomarkers and the Potential Role of Cancer Stem Cells
Langan, R. C., Mullinax, J. E., Raiji, M. T., Upham, T. C., Summers, T. A., Stojadinovic, A., & Avital, I. (2013) · Journal of Cancer · doi:10.7150/jca.5832 · Cited by 88
Targeted therapies in colorectal cancer—an integrative view by PPPM
Hagan, S., Orr, M. C. M., & Doyle, B. J. (2013) · The EPMA Journal · doi:10.1186/1878-5085-4-3 · Cited by 106
Leto, S. M., & Trusolino, L. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1161-2 · Cited by 87
Cushman, S. M., Jiang, C., Hatch, A. J., Shterev, I. D., Sibley, A. B., Niedzwiecki, D., Venook, A. P., Owzar, K., Hurwitz, H. I., & Nixon, A. B. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2313 · Cited by 91
MITF Modulates Therapeutic Resistance through EGFR Signaling
Ji, Z., Erin Chen, Y., Kumar, R., Taylor, M., Jenny Njauw, C.-N., Miao, B., Frederick, D. T., Wargo, J. A., Flaherty, K. T., Jönsson, G., et al. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2015.105 · Cited by 86
Strategies to tackle RAS-mutated metastatic colorectal cancer
Patelli, G., Tosi, F., Amatu, A., Mauri, G., Curaba, A., Patanè, D. A., Pani, A., Scaglione, F., Siena, S., & Sartore-Bianchi, A. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100156 · Cited by 86
Trusolino, L., & Bertotti, A. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0400 · Cited by 86
Varga, A., Soria, J.-C., Hollebecque, A., LoRusso, P., Bendell, J., Huang, S.-M. A., Wagle, M.-C., Okrah, K., Liu, L., Murray, E., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2574 · Cited by 87
Self-citationKlomp, J. E., Klomp, J. A., & Der, C. J. (2021) · Biochemical Society Transactions · doi:10.1042/bst20200507 · Cited by 91
Oncogenic BRAF, unrestrained by TGFβ-receptor signalling, drives right-sided colonic tumorigenesis
Leach, J. D. G., Vlahov, N., Tsantoulis, P., Ridgway, R. A., Flanagan, D. J., Gilroy, K., Sphyris, N., Vázquez, E. G., Vincent, D. F., Faller, W. J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23717-5 · Cited by 82
Organoid screening reveals epigenetic vulnerabilities in human colorectal cancer
Toshimitsu, K., Takano, A., Fujii, M., Togasaki, K., Matano, M., Takahashi, S., Kanai∥, T., & Sato, T. (2022) · Nature Chemical Biology · doi:10.1038/s41589-022-00984-x · Cited by 91
Couto, M., García, M. F., Alamón, C., Cabrera, M., Cabral, P., Merlino, A., Teixidor, F., Cerecetto, H., & Viñas, C. (2017) · Chemistry - A European Journal · doi:10.1002/chem.201705181 · Cited by 91
Feng, D., Qin, B., Pal, K., Sun, L., Dutta, S. K., Dong, H., Liu, X., Mukhopadhyay, D., Huang, S., & Sinicrope, F. A. (2019) · Oncogene · doi:10.1038/s41388-019-0919-y · Cited by 88
Self-citationDienstmann, R., Serpico, D., Rodon, J., Saura, C., Macarulla, T., Elez, E., Alsina, M., Capdevila, J., Perez-Garcia, J., Sánchez-Ollé, G., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0290 · Cited by 83
RAS and BRAF in metastatic colorectal cancer management
Gong, J., Cho, M., & Fakih, M. (2016) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2016.06.12 · Cited by 78
Histology-agnostic drug development — considering issues beyond the tissue
Pestana, R. C., Sen, S., Hobbs, B. P., & Hong, D. S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0384-0 · Cited by 88
Tang, Z., Yuan, X., Du, R., Cheung, S.-H., Zhang, G., Wei, J., Zhao, Y., Feng, Y., Peng, H., Zhang, Y., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0262 · Cited by 77
Gatalica, Z., Millis, S. Z., Vranić, S., Bender, R. P., Basu, G. D., Voß, A., & Hoff, D. D. V. (2014) · Oncotarget · doi:10.18632/oncotarget.2574 · Cited by 86
A Missing Link in Genotype-Directed Cancer Therapy
Bernards, R. (2012) · Cell · doi:10.1016/j.cell.2012.10.014 · Cited by 86
Self-citationComplex synthetic lethality in cancer
Ryan, C. J., Devakumar, L. J. P. S., Pettitt, S. J., & Lord, C. J. (2023) · Nature Genetics · doi:10.1038/s41588-023-01557-x · Cited by 83
Carlino, M. S., Gowrishankar, K., Saunders, C. A. B., Pupo, G. M., Snoyman, S., Zhang, X. D., Saw, R., Becker, T. M., Kefford, R. F., Long, G. V., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0011 · Cited by 82
Metadata
- Authors
- Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R.
- Affiliations
- The Netherlands Cancer Institute (NL)
- University of Turin (IT)
- IFOM (IT)
- Corresponding author
- Bernards, René
- ORCID
- Venue
- Nature
- Published
- 2012-01-26
- Volume
- 483
- Issue
- 7387
- Pages
- 100-103
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2014881369
- Semantic Scholar
- 10564d8dc4a3ddb05a84b5a3ca8b7b622c5c17ea
- Cited by
- 2,051
- References
- 22
- Citations by year
- 2026: 75 · 2025: 81 · 2024: 106 · 2023: 145 · 2022: 126 · 2021: 168 · 2020: 145 · 2019: 117 · 2018: 139 · 2017: 129 · 2016: 149 · 2015: 215 · 2014: 188 · 2013: 172 · 2012: 91
- FWCI
- 105.49
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- European Commission (259015)
- Ministero della Salute
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek
- KWF Kankerbestrijding
- Associazione Italiana per la Ricerca sul Cancro (5 x mille)
- Regione Piemonte
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- BRAF V600E mutation, colon cancer, EGFR, vemurafenib, drug resistance, feedback activation, cetuximab, gefitinib, erlotinib, combination therapy, RNAi screen, melanoma, targeted therapy
- MeSH terms
- Cetuximab, Erlotinib Hydrochloride, Gefitinib, Vemurafenib, Animals, Antibodies, Monoclonal, Antineoplastic Agents, Drug Synergism, Enzyme Activation, Female, Humans, Indoles, Melanoma, Quinazolines, Sulfonamides, Colorectal Neoplasms, Apoptosis, Drug Resistance, Neoplasm, Xenograft Model Antitumor Assays, Feedback, Physiological, RNA Interference, Cell Line, Tumor, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf, Cell Proliferation, Mice, HEK293 Cells, Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.